INOVIO, a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference:

American Association for Cancer Research – Immuno-Oncology
Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy (February 23-26, 2025)
Poster entitled: "Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107"

INOVIO is a clinical-stage biotechnology company committed to advancing DNA medicines to help save and protect lives worldwide. We are trailblazers in the DNA medicine field, working to develop and commercialize innovative, next-generation medicines to fight HPV-related diseases, cancer and infectious diseases.

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Source: prnewswire.com

Report Abuse